Skip to main content
Top

23-02-2024 | Obesity | REVIEW

Update on Endoscopic Treatments for Obesity

Authors: Fernanda Pessorrusso, Sagar V. Mehta, Shelby Sullivan

Published in: Current Obesity Reports

Login to get access

Abstract

Purpose of Review

Increased morbidity seen with rising obesity rates continues to place an unheralded burden on our health system. Lack of higher bariatric surgery utilization and limitations with lifestyle modification and pharmacotherapy highlights the need for additional therapies for obesity. Endoscopic bariatric and metabolic therapies (EBMT) are effective, safe treatments for obesity. Current FDA-approved EBMT are confined to gastric modalities while small bowel directed therapies are still considered investigational. This review highlights current modalities of EBMT.

Recent Findings

Many randomized controlled trials have been performed, including both open label and sham-controlled, which have demonstrated safety and efficacy of EBMT over lifestyle therapy alone. In addition, emerging evidence from clinical experience further supports EBMT for treatment of obesity.

Summary

Current evidence supports the safety and efficacy of EBMT for obesity treatment in conjunction with lifestyle therapy. They can also be used concurrently with weight loss medications to increase total weight loss.
Literature
1.
go back to reference Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;360:1–8. Epub 2020/06/04 PubMed PMID: 32487284. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;360:1–8. Epub 2020/06/04 PubMed PMID: 32487284.
3.
go back to reference Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–86. https://doi.org/10.1016/s0140-6736(09)61457-4. PubMed PMID: 19878986; PMCID: PMC3135022.CrossRefPubMed Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–86. https://​doi.​org/​10.​1016/​s0140-6736(09)61457-4. PubMed PMID: 19878986; PMCID: PMC3135022.CrossRefPubMed
7.
go back to reference Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O’Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT, Investigators S. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–13. https://doi.org/10.1001/jama.2021.1831.CrossRefPubMed Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O’Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT, Investigators S. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–13. https://​doi.​org/​10.​1001/​jama.​2021.​1831.CrossRefPubMed
11.
13.
go back to reference O’Brien PE, Hindle A, Brennan L, Skinner S, Burton P, Smith A, Crosthwaite G, Brown W. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019;29(1):3–14. https://doi.org/10.1007/s11695-018-3525-0.CrossRefPubMed O’Brien PE, Hindle A, Brennan L, Skinner S, Burton P, Smith A, Crosthwaite G, Brown W. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019;29(1):3–14. https://​doi.​org/​10.​1007/​s11695-018-3525-0.CrossRefPubMed
15.
go back to reference Courcoulas A, Coley RY, Clark JM, McBride CL, Cirelli E, McTigue K, Arterburn D, Coleman KJ, Wellman R, Anau J, Toh S, Janning CD, Cook AJ, Williams N, Sturtevant JL, Horgan C, Tavakkoli A, Collaborative ftPBS. Interventions and operations 5 years after bariatric surgery in a cohort from the US National Patient-Centered Clinical Research Network Bariatric Study. JAMA Surgery. 2020;155(3):194–204. https://doi.org/10.1001/jamasurg.2019.5470.CrossRefPubMedPubMedCentral Courcoulas A, Coley RY, Clark JM, McBride CL, Cirelli E, McTigue K, Arterburn D, Coleman KJ, Wellman R, Anau J, Toh S, Janning CD, Cook AJ, Williams N, Sturtevant JL, Horgan C, Tavakkoli A, Collaborative ftPBS. Interventions and operations 5 years after bariatric surgery in a cohort from the US National Patient-Centered Clinical Research Network Bariatric Study. JAMA Surgery. 2020;155(3):194–204. https://​doi.​org/​10.​1001/​jamasurg.​2019.​5470.CrossRefPubMedPubMedCentral
17.
go back to reference Sullivan S, Swain JM, Woodman G, Antonetti M, De La Cruz-Muñoz N, Jonnalagadda SS, Ujiki M, Ikramuddin S, Ponce J, Ryou M, Reynoso J, Chhabra R, Sorenson GB, Clarkston WK, Edmundowicz SA, Eagon JC, Mullady DK, Leslie D, Lavin TE, Thompson CC. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Obesity (Silver Spring). 2017;25(2):294–301. https://doi.org/10.1002/oby.21702. Epub 2016/12/22 PubMed PMID: 28000425.CrossRefPubMed Sullivan S, Swain JM, Woodman G, Antonetti M, De La Cruz-Muñoz N, Jonnalagadda SS, Ujiki M, Ikramuddin S, Ponce J, Ryou M, Reynoso J, Chhabra R, Sorenson GB, Clarkston WK, Edmundowicz SA, Eagon JC, Mullady DK, Leslie D, Lavin TE, Thompson CC. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Obesity (Silver Spring). 2017;25(2):294–301. https://​doi.​org/​10.​1002/​oby.​21702. Epub 2016/12/22 PubMed PMID: 28000425.CrossRefPubMed
21.
go back to reference Courcoulas A, Abu Dayyeh BK, Eaton L, Robinson J, Woodman G, Fusco M, Shayani V, Billy H, Pambianco D, Gostout C. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes (Lond). 2017;41(3):427–33. https://doi.org/10.1038/ijo.2016.229. Epub 2016/12/27 PubMed PMID: 28017964.CrossRefPubMed Courcoulas A, Abu Dayyeh BK, Eaton L, Robinson J, Woodman G, Fusco M, Shayani V, Billy H, Pambianco D, Gostout C. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes (Lond). 2017;41(3):427–33. https://​doi.​org/​10.​1038/​ijo.​2016.​229. Epub 2016/12/27 PubMed PMID: 28017964.CrossRefPubMed
22.
go back to reference FDA Code of Federal Regulations Title -21CFR803 Medical Device Reporting. FDA Code of Federal Regulations Title -21CFR803 Medical Device Reporting.
23.
go back to reference Abu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, Larsen M, Sullivan S, Thompson CC, Banerjee S. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425-38.e5. https://doi.org/10.1016/j.gie.2015.03.1964. Epub 2015/08/02 PubMed PMID: 26232362.CrossRefPubMed Abu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, Larsen M, Sullivan S, Thompson CC, Banerjee S. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425-38.e5. https://​doi.​org/​10.​1016/​j.​gie.​2015.​03.​1964. Epub 2015/08/02 PubMed PMID: 26232362.CrossRefPubMed
24.
go back to reference Vargas EJ, Pesta CM, Bali A, Ibegbu E, Bazerbachi F, Moore RL, Kumbhari V, Sharaiha RZ, Curry TW, DosSantos G, Schmitz R, Agnihotri A, Novikov AA, Pitt T, Dunlap MK, Herr A, Aronne L, Ledonne E, Kadouh HC, Cheskin LJ, Mundi MS, Acosta A, Gostout CJ, Abu Dayyeh BK. Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clin Gastroenterol Hepatol. 2018;16(7):1073-80.e1. https://doi.org/10.1016/j.cgh.2018.01.046. Epub 2018/02/10 PubMed PMID: 29425781; PMCID: PMC6008169.CrossRefPubMedPubMedCentral Vargas EJ, Pesta CM, Bali A, Ibegbu E, Bazerbachi F, Moore RL, Kumbhari V, Sharaiha RZ, Curry TW, DosSantos G, Schmitz R, Agnihotri A, Novikov AA, Pitt T, Dunlap MK, Herr A, Aronne L, Ledonne E, Kadouh HC, Cheskin LJ, Mundi MS, Acosta A, Gostout CJ, Abu Dayyeh BK. Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clin Gastroenterol Hepatol. 2018;16(7):1073-80.e1. https://​doi.​org/​10.​1016/​j.​cgh.​2018.​01.​046. Epub 2018/02/10 PubMed PMID: 29425781; PMCID: PMC6008169.CrossRefPubMedPubMedCentral
26.
go back to reference Sullivan S, Swain J, Woodman G, Edmundowicz S, Hassanein T, Shayani V, Fang JC, Noar M, Eid G, English WJ, Tariq N, Larsen M, Jonnalagadda SS, Riff DS, Ponce J, Early D, Volckmann E, Ibele AR, Spann MD, Krishnan K, Bucobo JC, Pryor A. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis. 2018;14(12):1876–89. https://doi.org/10.1016/j.soard.2018.09.486. Epub 2018/12/14 PubMed PMID: 30545596.CrossRefPubMed Sullivan S, Swain J, Woodman G, Edmundowicz S, Hassanein T, Shayani V, Fang JC, Noar M, Eid G, English WJ, Tariq N, Larsen M, Jonnalagadda SS, Riff DS, Ponce J, Early D, Volckmann E, Ibele AR, Spann MD, Krishnan K, Bucobo JC, Pryor A. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis. 2018;14(12):1876–89. https://​doi.​org/​10.​1016/​j.​soard.​2018.​09.​486. Epub 2018/12/14 PubMed PMID: 30545596.CrossRefPubMed
27.
go back to reference Moore RL, Seger MV, Garber SM, Smith AB, Nguyen RT, Shieh MK, Snow RG, Sullivan S. Clinical safety and effectiveness of a swallowable gas-filled intragastric balloon system for weight loss: consecutively treated patients in the initial year of U.S. commercialization. Surg Obes Relat Dis. 2019;15(3):417–23. https://doi.org/10.1016/j.soard.2018.12.007. Epub 2019/02/25 PubMed PMID: 30797717.CrossRefPubMed Moore RL, Seger MV, Garber SM, Smith AB, Nguyen RT, Shieh MK, Snow RG, Sullivan S. Clinical safety and effectiveness of a swallowable gas-filled intragastric balloon system for weight loss: consecutively treated patients in the initial year of U.S. commercialization. Surg Obes Relat Dis. 2019;15(3):417–23. https://​doi.​org/​10.​1016/​j.​soard.​2018.​12.​007. Epub 2019/02/25 PubMed PMID: 30797717.CrossRefPubMed
28.
29.
go back to reference Abu Dayyeh BK, Maselli DB, Rapaka B, Lavin T, Noar M, Hussan H, Chapman CG, Popov V, Jirapinyo P, Acosta A, Vargas EJ, Storm AC, Bazerbachi F, Ryou M, French M, Noria S, Molina D, Thompson CC. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet. 2021;398(10315):1965–73. https://doi.org/10.1016/S0140-6736(21)02394-1. Epub 20211115 PubMed PMID: 34793746.CrossRefPubMed Abu Dayyeh BK, Maselli DB, Rapaka B, Lavin T, Noar M, Hussan H, Chapman CG, Popov V, Jirapinyo P, Acosta A, Vargas EJ, Storm AC, Bazerbachi F, Ryou M, French M, Noria S, Molina D, Thompson CC. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet. 2021;398(10315):1965–73. https://​doi.​org/​10.​1016/​S0140-6736(21)02394-1. Epub 20211115 PubMed PMID: 34793746.CrossRefPubMed
30.
go back to reference Fittipaldi-Fernandez RJ, Zotarelli-Filho IJ, Diestel CF, Klein M, de Santana MF, de Lima JHF, Bastos FSS, Dos Santos NT. Randomized prospective clinical study of Spatz3(R) adjustable intragastric balloon treatment with a control group: a large-scale Brazilian experiment. Obes Surg. 2021;31(2):787–96. https://doi.org/10.1007/s11695-020-05014-0. Epub 20201001 PubMed PMID: 33001381.CrossRefPubMed Fittipaldi-Fernandez RJ, Zotarelli-Filho IJ, Diestel CF, Klein M, de Santana MF, de Lima JHF, Bastos FSS, Dos Santos NT. Randomized prospective clinical study of Spatz3(R) adjustable intragastric balloon treatment with a control group: a large-scale Brazilian experiment. Obes Surg. 2021;31(2):787–96. https://​doi.​org/​10.​1007/​s11695-020-05014-0. Epub 20201001 PubMed PMID: 33001381.CrossRefPubMed
39.
go back to reference Rothstein R, Woodman G, Swain J, Cruz N, Kushnir V, Pryor A, English W, Odstrcil E, Horgan S, Sullivan S. 1108 – Transpyloric shuttle treatment improves cardiometabolic risk factors and quality of life in patients with obesity: results from a randomized, double-blind, sham-controlled trial. Gastroenterology. 2019;156:S-237. https://doi.org/10.1016/S0016-5085(19)37393-7.CrossRef Rothstein R, Woodman G, Swain J, Cruz N, Kushnir V, Pryor A, English W, Odstrcil E, Horgan S, Sullivan S. 1108 – Transpyloric shuttle treatment improves cardiometabolic risk factors and quality of life in patients with obesity: results from a randomized, double-blind, sham-controlled trial. Gastroenterology. 2019;156:S-237. https://​doi.​org/​10.​1016/​S0016-5085(19)37393-7.CrossRef
40.
go back to reference Kumar N, Abu Dayyeh BK, Lopez-Nava Breviere G, Galvao Neto MP, Sahdala NP, Shaikh SN, Hawes RH, Gostout CJ, Goenka MK, Orillac JR, Alvarado A, Jirapinyo P, Zundel N, Thompson CC. Endoscopic sutured gastroplasty: procedure evolution from first-in-man cases through current technique. Surg Endosc. 2018;32(4):2159–64. https://doi.org/10.1007/s00464-017-5869-2. Epub 2017/10/28 PubMed PMID: 29075966; PMCID: PMC5845469.CrossRefPubMed Kumar N, Abu Dayyeh BK, Lopez-Nava Breviere G, Galvao Neto MP, Sahdala NP, Shaikh SN, Hawes RH, Gostout CJ, Goenka MK, Orillac JR, Alvarado A, Jirapinyo P, Zundel N, Thompson CC. Endoscopic sutured gastroplasty: procedure evolution from first-in-man cases through current technique. Surg Endosc. 2018;32(4):2159–64. https://​doi.​org/​10.​1007/​s00464-017-5869-2. Epub 2017/10/28 PubMed PMID: 29075966; PMCID: PMC5845469.CrossRefPubMed
41.
go back to reference Abu Dayyeh BK, Bazerbachi F, Vargas EJ, Sharaiha RZ, Thompson CC, Thaemert BC, Teixeira AF, Chapman CG, Kumbhari V, Ujiki MB, Ahrens J, Day C, Galvao Neto M, Zundel N, Wilson EB. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet. 2022;400(10350):441–51. https://doi.org/10.1016/s0140-6736(22)01280-6. Epub 20220728 PubMed PMID: 35908555.CrossRefPubMed Abu Dayyeh BK, Bazerbachi F, Vargas EJ, Sharaiha RZ, Thompson CC, Thaemert BC, Teixeira AF, Chapman CG, Kumbhari V, Ujiki MB, Ahrens J, Day C, Galvao Neto M, Zundel N, Wilson EB. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet. 2022;400(10350):441–51. https://​doi.​org/​10.​1016/​s0140-6736(22)01280-6. Epub 20220728 PubMed PMID: 35908555.CrossRefPubMed
42.
go back to reference Sharaiha RZ, Hajifathalian K, Kumar R, Saunders K, Mehta A, Ang B, Skaf D, Shah S, Herr A, Igel L, Dawod Q, Dawod E, Sampath K, Carr-Locke D, Brown R, Cohen D, Dannenberg AJ, Mahadev S, Shukla A, Aronne LJ. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol. 2020. Epub 2020/10/05. https://doi.org/10.1016/j.cgh.2020.09.055. PubMed PMID: 33011292. Sharaiha RZ, Hajifathalian K, Kumar R, Saunders K, Mehta A, Ang B, Skaf D, Shah S, Herr A, Igel L, Dawod Q, Dawod E, Sampath K, Carr-Locke D, Brown R, Cohen D, Dannenberg AJ, Mahadev S, Shukla A, Aronne LJ. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol. 2020. Epub 2020/10/05. https://​doi.​org/​10.​1016/​j.​cgh.​2020.​09.​055. PubMed PMID: 33011292.
43.
go back to reference Hedjoudje A, Abu Dayyeh BK, Cheskin LJ, Adam A, Neto MG, Badurdeen D, Morales JG, Sartoretto A, Nava GL, Vargas E, Sui Z, Fayad L, Farha J, Khashab MA, Kalloo AN, Alqahtani AR, Thompson CC, Kumbhari V. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18(5):1043-53.e4. https://doi.org/10.1016/j.cgh.2019.08.022. Epub 2019/08/24 PubMed PMID: 31442601.CrossRefPubMed Hedjoudje A, Abu Dayyeh BK, Cheskin LJ, Adam A, Neto MG, Badurdeen D, Morales JG, Sartoretto A, Nava GL, Vargas E, Sui Z, Fayad L, Farha J, Khashab MA, Kalloo AN, Alqahtani AR, Thompson CC, Kumbhari V. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18(5):1043-53.e4. https://​doi.​org/​10.​1016/​j.​cgh.​2019.​08.​022. Epub 2019/08/24 PubMed PMID: 31442601.CrossRefPubMed
46.
go back to reference Espinós JC, Turró R, Mata A, Cruz M, da Costa M, Villa V, Buchwald JN, Turró J. Early experience with the Incisionless Operating Platform™ (IOP) for the treatment of obesity : the primary obesity surgery endolumenal (POSE) procedure. Obes Surg. 2013;23(9):1375–83. https://doi.org/10.1007/s11695-013-0937-8. Epub 2013/04/18 PubMed PMID: 23591548.CrossRefPubMed Espinós JC, Turró R, Mata A, Cruz M, da Costa M, Villa V, Buchwald JN, Turró J. Early experience with the Incisionless Operating Platform™ (IOP) for the treatment of obesity : the primary obesity surgery endolumenal (POSE) procedure. Obes Surg. 2013;23(9):1375–83. https://​doi.​org/​10.​1007/​s11695-013-0937-8. Epub 2013/04/18 PubMed PMID: 23591548.CrossRefPubMed
49.
go back to reference Lopez-Nava G, Turro R, Maselli DB, Bautista-Castaño I, Matar R, Asokkumar R, Espinos JC, Mata A, Vargas EJ, Jaruvongvanich V, Storm AC, Neto MG, Abu Dayyeh BK. 720 Primary obesity surgery endoluminal 2 (POSE2): an international multicenter prospective trial. Gastrointest Endosc. 2020;91(6):AB60. https://doi.org/10.1016/j.gie.2020.03.584.CrossRef Lopez-Nava G, Turro R, Maselli DB, Bautista-Castaño I, Matar R, Asokkumar R, Espinos JC, Mata A, Vargas EJ, Jaruvongvanich V, Storm AC, Neto MG, Abu Dayyeh BK. 720 Primary obesity surgery endoluminal 2 (POSE2): an international multicenter prospective trial. Gastrointest Endosc. 2020;91(6):AB60. https://​doi.​org/​10.​1016/​j.​gie.​2020.​03.​584.CrossRef
50.
go back to reference Huberty V, Boskoski I, Bove V, Van Ouytsel P, Costamagna G, Barthet MA, Deviere J. Endoscopic sutured gastroplasty in addition to lifestyle modification: short-term efficacy in a controlled randomised trial. Gut. 2020. Epub 20201028. https://doi.org/10.1136/gutjnl-2020-322026. PubMed PMID: 33115727. Huberty V, Boskoski I, Bove V, Van Ouytsel P, Costamagna G, Barthet MA, Deviere J. Endoscopic sutured gastroplasty in addition to lifestyle modification: short-term efficacy in a controlled randomised trial. Gut. 2020. Epub 20201028. https://​doi.​org/​10.​1136/​gutjnl-2020-322026. PubMed PMID: 33115727.
54.
go back to reference Hajifathalian K, Mehta A, Shah S, Issa D, Dawod Q, Dawod E, Azzam M, Sampath K, Mahadev S, Mukewar S, Carr-Locke D, Kumar R, Aronne L, Shukla A, Sharaiha R. Tu1908 – Efficacy of pharmacotherapy in the treatment of weight regain and inadequate weight loss following endoscopic sleeve gastroplasty. Gastroenterology. 2019;156:S-1168. https://doi.org/10.1016/S0016-5085(19)39891-9.CrossRef Hajifathalian K, Mehta A, Shah S, Issa D, Dawod Q, Dawod E, Azzam M, Sampath K, Mahadev S, Mukewar S, Carr-Locke D, Kumar R, Aronne L, Shukla A, Sharaiha R. Tu1908 – Efficacy of pharmacotherapy in the treatment of weight regain and inadequate weight loss following endoscopic sleeve gastroplasty. Gastroenterology. 2019;156:S-1168. https://​doi.​org/​10.​1016/​S0016-5085(19)39891-9.CrossRef
55.
go back to reference Badurdeen D, Hoff AC, Hedjoudje A, Adam A, Itani MI, Farha J, Abbarh S, Kalloo AN, Khashab MA, Singh VK, Oberbach A, Neto MG, Barrichello S, Kumbhari V. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest Endosc. 2020. Epub 2020/10/20. https://doi.org/10.1016/j.gie.2020.10.016. PubMed PMID: 33075366. Badurdeen D, Hoff AC, Hedjoudje A, Adam A, Itani MI, Farha J, Abbarh S, Kalloo AN, Khashab MA, Singh VK, Oberbach A, Neto MG, Barrichello S, Kumbhari V. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest Endosc. 2020. Epub 2020/10/20. https://​doi.​org/​10.​1016/​j.​gie.​2020.​10.​016. PubMed PMID: 33075366.
57.
go back to reference Vantanasiri K, Matar R, Beran A, Jaruvongvanich V. The efficacy and safety of a procedureless gastric balloon for weight loss: a systematic review and meta-analysis. Obes Surg. 2020;30(9):3341-6. Epub 2020/04/09. doi: https://doi.org/10.1007/s11695-020-04522-3. PubMed PMID: 32266698. Vantanasiri K, Matar R, Beran A, Jaruvongvanich V. The efficacy and safety of a procedureless gastric balloon for weight loss: a systematic review and meta-analysis. Obes Surg. 2020;30(9):3341-6. Epub 2020/04/09. doi: https://​doi.​org/​10.​1007/​s11695-020-04522-3. PubMed PMID: 32266698.
58.
go back to reference Machytka E, Chuttani R, Bojkova M, Kupka T, Buzga M, Stecco K, Levy S, Gaur S. Elipse™, a procedureless gastric balloon for weight loss: a proof-of-concept pilot study. Obes Surg. 2016;26(3):512-6. https://doi.org/10.1007/s11695-015-1783-7. Epub 2015/08/09. PubMed PMID: 26253980. Machytka E, Chuttani R, Bojkova M, Kupka T, Buzga M, Stecco K, Levy S, Gaur S. Elipse™, a procedureless gastric balloon for weight loss: a proof-of-concept pilot study. Obes Surg. 2016;26(3):512-6. https://​doi.​org/​10.​1007/​s11695-015-1783-7. Epub 2015/08/09. PubMed PMID: 26253980.
59.
go back to reference Machytka E, Gaur S, Chuttani R, Bojkova M, Kupka T, Buzga M, Giannakou A, Ioannis K, Mathus-Vliegen E, Levy S, Raftopoulos I. Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study. Endoscopy. 2017;49(2):154-60. https://doi.org/10.1055/s-0042-119296. Epub 2016/12/13. PubMed PMID: 27951610. Machytka E, Gaur S, Chuttani R, Bojkova M, Kupka T, Buzga M, Giannakou A, Ioannis K, Mathus-Vliegen E, Levy S, Raftopoulos I. Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study. Endoscopy. 2017;49(2):154-60. https://​doi.​org/​10.​1055/​s-0042-119296. Epub 2016/12/13. PubMed PMID: 27951610.
63.
go back to reference Rodriguez L, Reyes E, Fagalde P, Oltra MS, Saba J, Aylwin CG, Prieto C, Ramos A, Galvao M, Gersin KS, Sorli C. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009;11(11):725-32. https://doi.org/10.1089/dia.2009.0063. Epub 2009/11/13. PubMed PMID: 19905889. Rodriguez L, Reyes E, Fagalde P, Oltra MS, Saba J, Aylwin CG, Prieto C, Ramos A, Galvao M, Gersin KS, Sorli C. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009;11(11):725-32. https://​doi.​org/​10.​1089/​dia.​2009.​0063. Epub 2009/11/13. PubMed PMID: 19905889.
64.
go back to reference Gersin KS, Rothstein RI, Rosenthal RJ, Stefanidis D, Deal SE, Kuwada TS, Laycock W, Adrales G, Vassiliou M, Szomstein S, Heller S, Joyce AM, Heiss F, Nepomnayshy D. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976-82. https://doi.org/10.1016/j.gie.2009.11.051. Epub 2010/03/23. PubMed PMID: 20304396. Gersin KS, Rothstein RI, Rosenthal RJ, Stefanidis D, Deal SE, Kuwada TS, Laycock W, Adrales G, Vassiliou M, Szomstein S, Heller S, Joyce AM, Heiss F, Nepomnayshy D. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976-82. https://​doi.​org/​10.​1016/​j.​gie.​2009.​11.​051. Epub 2010/03/23. PubMed PMID: 20304396.
65.
go back to reference Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM, Greve JW. A multicenter, randomized efficacy study of the endobarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236-43. https://doi.org/10.1097/SLA.0b013e3181bdfbff. Epub 2009/10/28. PubMed PMID: 19858703. Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM, Greve JW. A multicenter, randomized efficacy study of the endobarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236-43. https://​doi.​org/​10.​1097/​SLA.​0b013e3181bdfbff​. Epub 2009/10/28. PubMed PMID: 19858703.
66.
go back to reference Tarnoff M, Rodriguez L, Escalona A, Ramos A, Neto M, Alamo M, Reyes E, Pimentel F, Ibanez L. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc. 2009;23(3):650-6. https://doi.org/10.1007/s00464-008-0125-4. Epub 2008/12/11. PubMed PMID: 19067075. Tarnoff M, Rodriguez L, Escalona A, Ramos A, Neto M, Alamo M, Reyes E, Pimentel F, Ibanez L. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc. 2009;23(3):650-6. https://​doi.​org/​10.​1007/​s00464-008-0125-4. Epub 2008/12/11. PubMed PMID: 19067075.
67.
go back to reference Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care. 2018;41(5):1106–15. https://doi.org/10.2337/dc17-1985. PubMed PMID: 29678867.CrossRefPubMed Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care. 2018;41(5):1106–15. https://​doi.​org/​10.​2337/​dc17-1985. PubMed PMID: 29678867.CrossRefPubMed
68.
go back to reference Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984-92. https://doi.org/10.1097/sla.0000000000000794. Epub 2014/07/30. PubMed PMID: 25072436. Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984-92. https://​doi.​org/​10.​1097/​sla.​0000000000000794​. Epub 2014/07/30. PubMed PMID: 25072436.
69.
go back to reference Kaplan LM BJ, Mullin C, Edmundowicz SA, Bass E, Visintainer P, et al, editor. EndoBarrier therapy is associated with glycemic improvement, weight loss and safety issues in patients with obesity and type 2 diabetes on oral antihyperglycemic agents. American Diabetes Association; 2016; New Orleans, LA. Kaplan LM BJ, Mullin C, Edmundowicz SA, Bass E, Visintainer P, et al, editor. EndoBarrier therapy is associated with glycemic improvement, weight loss and safety issues in patients with obesity and type 2 diabetes on oral antihyperglycemic agents. American Diabetes Association; 2016; New Orleans, LA.
70.
80.
go back to reference Rajagopalan H, Cherrington AD, Thompson CC, Kaplan LM, Rubino F, Mingrone G, Becerra P, Rodriguez P, Vignolo P, Caplan J, Rodriguez L, Galvao Neto MP. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39(12):2254–61. https://doi.org/10.2337/dc16-0383. Epub 2016/08/16 PubMed PMID: 27519448.CrossRefPubMed Rajagopalan H, Cherrington AD, Thompson CC, Kaplan LM, Rubino F, Mingrone G, Becerra P, Rodriguez P, Vignolo P, Caplan J, Rodriguez L, Galvao Neto MP. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39(12):2254–61. https://​doi.​org/​10.​2337/​dc16-0383. Epub 2016/08/16 PubMed PMID: 27519448.CrossRefPubMed
81.
go back to reference van Baar ACG, Holleman F, Crenier L, Haidry R, Magee C, Hopkins D, Rodriguez Grunert L, Galvao Neto M, Vignolo P, Hayee B, Mertens A, Bisschops R, Tijssen J, Nieuwdorp M, Guidone C, Costamagna G, Devière J, Bergman J. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. 2020;69(2):295–303. https://doi.org/10.1136/gutjnl-2019-318349. Epub 2019/07/25 PubMed PMID: 31331994; PMCID: PMC6984054.CrossRefPubMed van Baar ACG, Holleman F, Crenier L, Haidry R, Magee C, Hopkins D, Rodriguez Grunert L, Galvao Neto M, Vignolo P, Hayee B, Mertens A, Bisschops R, Tijssen J, Nieuwdorp M, Guidone C, Costamagna G, Devière J, Bergman J. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. 2020;69(2):295–303. https://​doi.​org/​10.​1136/​gutjnl-2019-318349. Epub 2019/07/25 PubMed PMID: 31331994; PMCID: PMC6984054.CrossRefPubMed
82.
go back to reference Mingrone G, van Baar AC, Devière J, Hopkins D, Moura E, Cercato C, Rajagopalan H, Lopez-Talavera JC, White K, Bhambhani V, Costamagna G, Haidry R, Grecco E, Galvao Neto M, Aithal G, Repici A, Hayee BH, Haji A, Morris AJ, Bisschops R, Chouhan MD, Sakai NS, Bhatt DL, Sanyal AJ, Bergman JJGHM. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut. 2021:gutjnl-2020-323608. https://doi.org/10.1136/gutjnl-2020-323608. Mingrone G, van Baar AC, Devière J, Hopkins D, Moura E, Cercato C, Rajagopalan H, Lopez-Talavera JC, White K, Bhambhani V, Costamagna G, Haidry R, Grecco E, Galvao Neto M, Aithal G, Repici A, Hayee BH, Haji A, Morris AJ, Bisschops R, Chouhan MD, Sakai NS, Bhatt DL, Sanyal AJ, Bergman JJGHM. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut. 2021:gutjnl-2020-323608. https://​doi.​org/​10.​1136/​gutjnl-2020-323608.
Metadata
Title
Update on Endoscopic Treatments for Obesity
Authors
Fernanda Pessorrusso
Sagar V. Mehta
Shelby Sullivan
Publication date
23-02-2024
Publisher
Springer US
Published in
Current Obesity Reports
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-024-00551-6